$IART (Integra LifeSciences Holdings Corporation)

$IART {{ '2016-01-07T19:38:37+0000' | timeago}} • Announcement

Medical equipment, supplies & distribution company $IART said that the U.S. FDA has approved the PMA Supplement for Integra Dermal Regeneration Template for the treatment of diabetic foot ulcers. The advanced active healing dressings market is about $3Bil in the U.S., of which nearly $600MM is in cellular and tissue-based products.

$IART {{ '2018-01-08T12:15:32+0000' | timeago}} • Announcement

$IART said it expects 4Q17 revenue to be approx $365MM, an increase of over 40% compared to 4Q16, helped by Derma Sciences and Codman Neurosurgery acquisitions. The results will be announced in late February, 2018.

$JNJ {{ '2017-10-02T21:24:15+0000' | timeago}} • Announcement

$JNJ completed divestiture of its Codman Neurosurgery business to $IART for about $1.045Bil. The Codman Neurosurgery business offers a portfolio of devices focused on hydrocephalus management, neuro intensive care and cranial surgery, and generated net revenues of about $371.5MM in 2016.

$IART {{ '2017-10-02T20:12:26+0000' | timeago}} • Announcement

$IART closed acquisition of the Johnson & Johnson Codman Neurosurgery business for about $1.045Bil less customary adjustments, enhancing $IART's position as a global provider of neurosurgical products. $IART expects to close the previously announced divestiture of certain neurosurgery assets in the coming days.

$BABY {{ '2017-09-11T14:02:00+0000' | timeago}} • Announcement

$BABY has agreed to acquire certain neurosurgery business assets from $IART for $47.5MM. The divestiture by $IART is contingent on the consummation of its proposed acquisition of Codman Neurosurgery. Both transactions are expected to close in October 2017. $BABY expects the acquisition to be immediately accretive to non-GAAP earnings.

$BABY {{ '2017-09-11T11:55:35+0000' | timeago}} • Announcement

$BABY has entered into a definitive agreement with $IART, under which $BABY will acquire certain neurosurgery business assets from $IART for $47.5MM. The transaction is expected to close in October 2017, after regulatory clearance.

$IART {{ '2017-05-23T13:43:31+0000' | timeago}} • Announcement

$IART signed an agreement with Berlin-based medical device company aap Implantate AG (aap) to distribute its wrist plating system within the United States.

$IART {{ '2017-04-05T14:01:20+0000' | timeago}} • Announcement

$IART plans to use $700MM of the incremental term loan, together with borrowings from the existing revolving facility, to finance the acquisition of Codman Neurosurgery from $JNJ, which was announced on Feb. 15, 2017. Borrowings from the existing revolving facility will also be used to cover fees and expenses.

$IART {{ '2017-04-05T13:59:46+0000' | timeago}} • Announcement

$IART increased its credit facility with its bank group led by Bank of America, N.A. The facility includes an increase in the credit facility from $1.5Bil to $2.2Bil, $700MM incremental term loan will be made available in a single drawing on delayed basis, rise in total leverage ratio to 5.5 times EBITDA, no pricing terms and maturity change.

$IART {{ '2017-03-28T13:42:04+0000' | timeago}} • Announcement

$IART announced the full commercial availability of a new ankle prosthesis "Cadence Total Ankle System" in the United States, Canada, and select European countries. Integra plans to initiate several global post-market clinical studies with the Cadence system to further support product efficacy.

$IART {{ '2017-02-24T20:31:50+0000' | timeago}} • Announcement

$IART said that a tender offer by its subsidiary Integra Derma to buy all outstanding common and preferred shares of $DSCI at an offer price of $7.00 per common share, $32.00 per Series A Convertible Preferred share and $48.00 per Series B Convertible Preferred share, expired as scheduled on Feb. 22, 2017.

$IART {{ '2017-02-15T14:38:12+0000' | timeago}} • Announcement

$IART expects the Codman transaction with $JNJ to be accretive to adjusted EPS by at least $0.22 in the first full year after closing and increasing thereafter, and to GAAP EPS by the end of the third year. $IART expects the Codman Neurosurgery revenue to experience some initial disruption in the first year, and to then grow 3-6% longer term.

$IART {{ '2017-02-15T14:37:52+0000' | timeago}} • Announcement

$IART has made a binding offer to acquire $JNJ’s Codman Neurosurgery business for $1.045Bil in cash. The transaction is subject to regulatory approvals and is expected to close in two steps, first, in the approx. 24 principal countries during 4Q17, and subsequently, in the remaining countries on a rolling basis.

$IART {{ '2017-01-25T15:18:23+0000' | timeago}} • Announcement

$IART said its subsidiary Integra Derma is commencing cash tender offer to buy all outstanding common and preferred shares of $DSCI at $7.00 per share for $DSCI common stock, $32.00 per share for $DSCI's Series A Convertible Preferred Stock and $48.00 per share for Series B Convertible Preferred Stock. The tender offer will expire on Feb. 22.

$IART {{ '2016-12-22T13:54:34+0000' | timeago}} • Announcement

$IART's stockholders approved a 2-for-1 stock split and an increase from 60MM to 240MM authorized common shares. Holders of record, on Dec. 21, 2016, will be entitled to receive 1 additional common share for each share held and expected to be distributed on Jan. 3, 2017. The adjusted stock price is likely to be reflected on Nasdaq on Jan. 4, 2017.

$IART {{ '2016-12-07T18:27:03+0000' | timeago}} • Announcement

$IART lifted its credit facility with its bank group led by Bank of America. The expanded and extended credit facility includes: a rise from $1.1Bil to $1.5Bil, consisting of a $1Bil revolving line of credit and term loan of $500MM.. This also includes option to rise aggregate size by at least $250MM and maturity date is extended to Dec. 7, 2021.

$IART {{ '2016-12-05T14:08:42+0000' | timeago}} • Announcement

$IART appointed Robert Davis Jr. as corporate VP and president, Orthopedics and Tissue Technologies. Dan Reuvers will assume corporate VP and president, Specialty Surgical Solutions (SSS). Glenn Coleman, corporate VP, CFO and principal accounting officer, will also assume oversight of international business. These are effective Dec. 1, 2016.

$IART {{ '2016-05-11T13:48:07+0000' | timeago}} • Announcement

$IART said it received approval from the U.S. Food and Drug Administration for the packaging of its new product, Integra Omnigraft Dermal Regeneration Matrix, which clears the way for its commercial release. The product's packaging is designed for ease of handling and application in the outpatient wound care setting, the company said.

$IART {{ '2016-04-27T13:18:48+0000' | timeago}} • Announcement

$IART said it is prepared to launch Omnigraft Dermal Regeneration Matrix in June 2016, pending receipt of final U.S. Food and Drug Administration (FDA) packaging approval. The FDA approved PMA Supplement for Integra Dermal Regeneration Template (IDRT) for treatment of diabetic foot ulcers (DFUs) on Jan. 7.

$IART {{ '2016-04-14T14:16:48+0000' | timeago}} • Announcement

Medical technology company $IART said its subsidiary, Integra LifeSciences Corporation, has entered into an agreement with Vomaris Wound Care, Inc. Under the agreement, Integra has exclusive rights to market and sell Vomaris's Advanced Microcurrent Technology to manage chronic and acute wounds, including burns and surgical incisional wounds.

$IART {{ '2016-03-10T20:07:51+0000' | timeago}} • Announcement

Medical technology company $IART said that through the Buffalo Supply partnership, it has received a five-year, $10.3MM contract with the DoD to provide access to its Specialty Surgical Solutions and Orthopedics & Tissue Technology products. The contract is intended for the Defense Logistics Agency (DLA) Medical Electronic Catalogue (ECAT).

Recent Transcripts

WOR (Worthington Industries, Inc.)
Tuesday, December 19 2017 - 7:30pm
MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
A (Agilent Technologies Inc.)
Monday, November 20 2017 - 9:30pm
AIRI (Air Industries Group)
Thursday, November 16 2017 - 1:30pm
COHR (Coherent Inc.)
Tuesday, November 7 2017 - 9:30pm
PSDV (pSivida Corp.)
Tuesday, November 7 2017 - 1:30pm
IRIX (IRIDEX Corporation)
Thursday, November 2 2017 - 9:00pm
FLDM (Fluidigm Corporation)
Thursday, November 2 2017 - 9:00pm
MTD (Mettler-Toledo International Inc.)
Thursday, November 2 2017 - 9:00pm
PKI (PerkinElmer Inc.)
Thursday, November 2 2017 - 9:00pm
PACB (Pacific Biosciences of California, Inc.)
Thursday, November 2 2017 - 8:30pm
WMGI (Wright Medical Group N.V.)
Wednesday, November 1 2017 - 8:30pm
STE (Steris Plc)
Wednesday, November 1 2017 - 2:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
LBY (Libbey Inc.)
Tuesday, October 31 2017 - 3:00pm
XYL (Xylem Inc.)
Tuesday, October 31 2017 - 1:00pm
CRY (CryoLife Inc.)
Tuesday, October 31 2017 - 12:00pm
IART (Integra LifeSciences Holdings Corporation)
Thursday, October 26 2017 - 12:30pm
MDCO (The Medicines Company)
Wednesday, October 25 2017 - 12:30pm
ILMN (Illumina Inc.)
Tuesday, October 24 2017 - 9:00pm

AlphaGraphics you may like